No Data
Express News | [Large Shareholding Report] Hama Medical Services reports a 7.34% Shareholding in Beemap (4316.JP).
Kid's Bio and other attractive stocks viewed from the changes in Volume.
Stock closing prices compared to the previous day and Volume * <6147> Yamazaki 30,114,790,700 * <3372> Kanmon Marine 22,610,161,6400 * <4584> Kids Bio 13,621,396,06600 * <4319> TAC 20,781,220,900 * <6063> EAJ 12,576,816,9200 * <7538> Oomizu 31,817,304,800 * <3682> Encourage 60,626,109,800 * <6662> Ubitec 22,011,702,00 * <2424> Blass 5
Ribomic, BTM and others [Emerging Markets press release]
＜290A＞ Recognized approximately 0.017 billion yen in subsidy income as non-operating revenue. ＜4316＞ Acquired real estate for sale in Beemap (land in Kawasaki City, Kanagawa Prefecture). ＜4379＞ Completed the acquisition of treasury stock for Photosync. ＜4591＞ Released the results of joint research on ANCA-related vasculitis with Hokkaido Universities and concluded the joint research contract. ＜5070＞ Established a subsidiary, Draft. ＜5247＞ Acquired shares of a company engaged in the design, manufacturing, sales, and maintenance of BTM Computer software.
Timy and other stocks that are interesting based on changes in Volume.
Stock closing price change Volume * <4316> Beamap 433801 445600 * <3930> Hatena 140215 7202300 * <1905> Tenox 116816 58900 * <2164> Regional Newspaper Company 388271 19100 * <7692> E-Infinity 115307 717800 * <9218> Mental Health T 788331 29700 * <4571> NANO MRNAs 159 15 1356500 * <219A> Heart S
Stocks hitting the upper and lower limits before the market.
■Limit-up ＜3747＞ Intertrade ＜3987＞ Ecomot ＜4194＞ Visional ＜4316＞ Beamap ＜5035＞ HOUSEI ＜6614＞ Shikino High-Tech ＜8142＞ Toho ＜9238＞ Value Creation ■Limit-down *Includes temporary limit-up and limit-down (indicative prices).
Individual stock information.
BTM <5247.T> rebounded significantly after eight days of decline. A 1-for-2 Stock Splits will be carried out with March 31 as the record date and April 1 as the effective date. Palma <3461.T> continued to rise significantly. It will change markets from the Tokyo Growth Market to the Tokyo Standard Market on the 7th. DeltaF <4598.T> rebounded. The Phase 1 portion (dose setting) of the clinical trial for 'DFP-10917' in combination with 'Venetoclax (VEN)' targeting patients with acute myeloid leukemia in the second-line treatment.